ImmunOs Therapeutics AG Receives Public Funding from Eurostars and Innosuisse for a Novel Therapeutic Antibody to Treat Inflammatory Rheumatic Diseases
– ImmunOs Therapeutics AG, a Swiss bio-technology company developing a new class of biologics for the treatment of cancer and autoimmune diseases, announced today that is has received public funding from the European Union’s Eurostars-2 Programme and the Swiss Innovation Agency Innosuisse. The funds have been granted for the development of a pioneering HLA-open conformer-specific Read more about ImmunOs Therapeutics AG Receives Public Funding from Eurostars and Innosuisse for a Novel Therapeutic Antibody to Treat Inflammatory Rheumatic Diseases[…]